RARE Stock Overview
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Ultragenyx Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.24 |
| 52 Week High | US$60.37 |
| 52 Week Low | US$37.02 |
| Beta | 0.58 |
| 11 Month Change | -12.23% |
| 3 Month Change | -17.20% |
| 1 Year Change | 20.69% |
| 33 Year Change | -38.24% |
| 5 Year Change | 19.14% |
| Change since IPO | 11.81% |
Recent News & Updates
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
Nov 12Ultragenyx: Excellent Company, Lackluster Stock
Nov 06Recent updates
Ultragenyx: Ready For More Growth After Q3 Earnings Beat
Nov 12Ultragenyx: Excellent Company, Lackluster Stock
Nov 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
Sep 04
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
Aug 22There's Reason For Concern Over Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Massive 26% Price Jump
Aug 03Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Shareholder Returns
| RARE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.6% | 2.5% | 2.2% |
| 1Y | 20.7% | 16.1% | 31.6% |
Return vs Industry: RARE exceeded the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: RARE underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| RARE volatility | |
|---|---|
| RARE Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RARE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RARE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,276 | Emil Kakkis | www.ultragenyx.com |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. Fundamentals Summary
| RARE fundamental statistics | |
|---|---|
| Market cap | US$4.36b |
| Earnings (TTM) | -US$558.99m |
| Revenue (TTM) | US$522.75m |
8.3x
P/S Ratio-7.8x
P/E RatioIs RARE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RARE income statement (TTM) | |
|---|---|
| Revenue | US$522.75m |
| Cost of Revenue | US$720.33m |
| Gross Profit | -US$197.59m |
| Other Expenses | US$361.40m |
| Earnings | -US$558.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.06 |
| Gross Margin | -37.80% |
| Net Profit Margin | -106.93% |
| Debt/Equity Ratio | 248.3% |
How did RARE perform over the long term?
See historical performance and comparison